Core Insights - SureNano Science Ltd. has acquired GlucaPharm Inc., enhancing its position in the pharmaceutical market focused on obesity and metabolic diseases with the development of GEP44, a next-generation glucagon-like peptide (GLP) [2][8] Company Overview - GlucaPharm is developing GEP44, a patented peptide that aims to provide weight reduction and blood glucose normalization with fewer side effects compared to existing GLP-1 drugs like Ozempic® and Wegovy® [5][10] - SureNano Science Ltd. is transitioning from an enabling-technology company to a pharmaceutical value creator, targeting the rapidly growing global drug market [2][8] Acquisition Details - The acquisition was structured as a share exchange, with SureNano issuing 8,100,999 common shares and warrants for 5,000,000 common shares to GlucaPharm shareholders [3] - The shares issued will have a hold period until certain conditions are met, including approval from the Canadian Securities Exchange [3] Leadership and Expertise - Dr. Nihar R. Pandey has been appointed as Director and Chief Scientific Officer, bringing over 25 years of experience in drug discovery and development [4] Product Development - GEP44 is expected to advance through an IND-enabling FDA study and Phase I Clinical Trial in Australia, with key milestones anticipated in the next six to nine months [7][9] - The global GLP market is currently dominated by injectable therapies, and GlucaPharm aims to develop non-injectable delivery methods to enhance patient adoption [6][9] Market Potential - The GLP-1 metabolic market is projected to be multi-hundred-billion dollars, and SureNano aims to position itself as a significant player alongside large pharmaceutical companies [9]

Core Points - SureNano Science Ltd. has granted 1,500,000 stock options to various directors, officers, and consultants, which will vest immediately and can be exercised at CAD $0.18 per share for a period of 5 years [1] - Following this grant, the total stock options represent 4.4% of the outstanding common shares of the Company [2] Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound that enables the creation of high-performance nano-emulsions, enhancing product stability, bioavailability, clarity, and taste [3] - The Company holds an exclusive license to distribute the SureNano™ surfactant in Canada and Colorado, USA [3]

Core Viewpoint - SureNano Science Ltd. has successfully closed a non-brokered private placement, raising $1,250,000 through the issuance of 10,000,000 units at a price of $0.125 per unit [1] Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the holder to acquire one common share at a price of $0.35 for 24 months [2] - The warrants are subject to an acceleration provision, allowing the company to expedite the expiry if its shares trade at $0.50 or greater for ten consecutive trading days [2] - The company paid cash commissions of $75,000 and issued 600,000 finder's warrants to brokerage firms for introducing subscribers [4] Group 2: Use of Proceeds - The proceeds from the private placement will be used for operating expenses, including legal and audit fees, general working capital, and exploring new markets for its SureNano™ surfactant [6] - Additionally, the funds may be allocated towards potential business combinations or acquisitions if approved by the Board [6] Group 3: Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound that enhances the performance of nanoemulsions [7] - The company holds an exclusive license to distribute the SureNano™ surfactant in Canada and specific regions in the USA, including Oklahoma and Colorado [7]

Core Viewpoint - SureNano Science Ltd. has entered into a non-binding letter of intent with GlucaPharm Inc. to explore a proposed transaction for the development of a GLP-1 drug, GEP-44, which targets diabetes and weight loss with a no-needle administration method and improved tolerability [1][2] Proposed Transaction Overview - The proposed transaction is structured as a share exchange, where SureNano will acquire 100% of GlucaPharm's common shares, with GlucaPharm shareholders expected to own under 20% of SureNano's shares post-transaction [3][4] - The transaction is subject to customary due diligence, negotiation of a definitive agreement, and necessary regulatory approvals [4] GlucaPharm's Product Details - GlucaPharm holds exclusive rights to develop GEP-44, a novel GLP-1 compound that aims to improve treatment for obesity and diabetes, showing strong preclinical results and academic validation [2] Private Placement - SureNano announced a private placement to raise up to $1,250,000 by selling up to 10,000,000 units at $0.125 per unit, with each unit consisting of one common share and one warrant [6][7] - Proceeds from the private placement will be used for operating expenses, including legal fees and market exploration, and are not dependent on the acquisition of GlucaPharm [8] Company Background - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, which enhances the performance of nanoemulsions, and holds exclusive distribution rights in Canada and certain U.S. states [9]

Core Viewpoint - SureNano Science Ltd. is planning a private placement to raise up to $1,250,000 through the sale of units, which will include common shares and purchase warrants [1][2]. Group 1: Private Placement Details - The private placement will consist of up to 10,000,000 units priced at $0.125 each, with each unit comprising one common share and one warrant [2]. - Each warrant allows the holder to purchase one common share at $0.35 for 24 months, with an acceleration provision if the share price exceeds $0.50 for ten consecutive trading days [2]. - Finders introducing subscribers may receive a 6% cash commission and 6% in common share purchase warrants, also exercisable at $0.35 for 24 months [3]. Group 2: Use of Proceeds - Proceeds from the private placement will be allocated for operating expenses, including legal and audit fees, and general working capital [3]. - The company aims to explore new markets for its SureNano™ surfactant and investigate complementary industries [3]. Group 3: Company Overview - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound for high-performance nanoemulsions [5]. - The company holds an exclusive license to distribute the SureNano™ surfactant in Canada, Oklahoma, and Colorado [5].

Group 1 - SureNano Science Ltd. has closed a private placement financing of 2,450,000 common shares at a price of $0.10 per share, raising total proceeds of $245,000, which includes $85,000 in debt conversion [1][2] - The proceeds from the financing will be allocated for operating expenses, including legal and audit fees, as well as general working capital, with no funds directed towards investor relations activities [2] - Charles Malette, a related party and the President, Secretary, and director of SureNano, participated in the private placement by purchasing shares for $110,000 cash and converting $85,000 in debt, resulting in him owning 9,621,600 shares, which is 40% of the common shares issued [3] Group 2 - SureNano Science Ltd. specializes in the sale and distribution of the SureNano™ surfactant, a food-grade compound designed for high-performance nanoemulsions that enhance product stability, bioavailability, clarity, and taste [4] - The company holds an exclusive license to distribute the SureNano™ surfactant in Canada, Oklahoma, and Colorado [4]